Literature DB >> 14726072

Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer.

Jeffrey L Port1, Michael S Kent, Robert J Korst, Roger Keresztes, Matthew A Levin, Nasser K Altorki.   

Abstract

BACKGROUND: The ability to accurately predict pathologic response to preoperative chemotherapy may have a significant impact on the treatment strategy for non-small cell lung cancer (NSCLC). The purpose of this study was to examine the accuracy of positron emission tomography (PET) scanning in predicting the pathologic response to preoperative chemotherapy in the primary tumor and draining lymph nodes.
METHODS: A total of 25 patients were enrolled in two separate phase II trials investigating induction chemotherapy for NSCLC. All patients underwent pre-treatment and post-treatment PET scans followed by surgical resection. A significant PET scan response was defined as a reduction in the standard uptake value by 50% or more. We defined a major pathologic response as either no disease or microscopic disease only in the primary tumor. The percentage change in standard uptake value was then calculated and correlated with pathologic response in the primary tumor. In addition, the presence or absence of nodal metastases as determined by the postchemotherapy PET scan was compared with final pathologic nodal stage.
RESULTS: The positive and negative predictive values for PET detection of major pathologic response in the primary tumor were 43% and 100%, respectively. Positron emission tomography did not accurately predict nodal status in 52% of patients. The positive and negative predictive values of PET to detect node-positive disease were 73% and 64%, respectively. For N2 disease the positive predictive value of PET scans was less than 20%.
CONCLUSIONS: Positron emission tomography scanning does not reliably predict pathologic response to preoperative chemotherapy in NSCLC in either the primary tumor or the draining lymph nodes.

Entities:  

Mesh:

Year:  2004        PMID: 14726072     DOI: 10.1016/s0003-4975(03)01457-7

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  14 in total

Review 1.  Monitoring chemotherapy and radiotherapy of solid tumors.

Authors:  Wolfgang A Weber; Hinrich Wieder
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07       Impact factor: 9.236

2.  Prognostic factors in non-small cell lung cancer patients who received neoadjuvant therapy and curative resection.

Authors:  Chen-Ping Hsieh; Ming-Ju Hsieh; Ching-Feng Wu; Jui-Ying Fu; Yun-Hen Liu; Yi-Cheng Wu; Cheng-Ta Yang; Ching-Yang Wu
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

Review 3.  The use and misuse of positron emission tomography in lung cancer evaluation.

Authors:  Ching-Fei Chang; Afshin Rashtian; Michael K Gould
Journal:  Clin Chest Med       Date:  2011-12       Impact factor: 2.878

4.  18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer.

Authors:  Susanne Martina Eschmann; Godehard Friedel; Frank Paulsen; Matthias Reimold; Thomas Hehr; Wilfried Budach; Heinz-Jakob Langen; Roland Bares
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-11-14       Impact factor: 9.236

5.  The usefulness of combined diagnostic CT and (99m)Tc-octreotide somatostatin receptor SPECT/CT imaging on pulmonary nodule characterization in patients.

Authors:  Liwei Wang; Xindao Yin; Feng Wang; Jianping Gu; Lingquan Lu; Qianzhi Wu; Baozhong Shen; Xiao-Feng Li
Journal:  Cancer Biother Radiopharm       Date:  2013-10-05       Impact factor: 3.099

6.  Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non-small cell lung cancer.

Authors:  R Taylor Ripley; Kei Suzuki; Kay See Tan; Prasad S Adusumilli; James Huang; Bernard J Park; Robert J Downey; Nabil P Rizk; Valerie W Rusch; Manjit Bains; David R Jones
Journal:  J Thorac Cardiovasc Surg       Date:  2015-10-19       Impact factor: 5.209

Review 7.  From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.

Authors:  Richard L Wahl; Heather Jacene; Yvette Kasamon; Martin A Lodge
Journal:  J Nucl Med       Date:  2009-05       Impact factor: 10.057

8.  Utility of Routine PET Imaging to Predict Response and Survival After Induction Therapy for Non-Small Cell Lung Cancer.

Authors:  Stephen A Barnett; Robert J Downey; Junting Zheng; Gabriel Plourde; Ronglai Shen; Jamie Chaft; Timothy Akhurst; Bernard J Park; Valerie W Rusch
Journal:  Ann Thorac Surg       Date:  2016-01-12       Impact factor: 4.330

9.  Prospective phase II trial of preresection thoracoscopic mediastinal restaging after neoadjuvant therapy for IIIA (N2) non-small cell lung cancer: results of CALGB Protocol 39803.

Authors:  Michael T Jaklitsch; Lin Gu; Todd Demmy; David H Harpole; Thomas A D'Amico; Robert J McKenna; Mark J Krasna; Leslie J Kohman; Scott J Swanson; Malcolm M DeCamp; Xiaofei Wang; Susan Barry; David J Sugarbaker
Journal:  J Thorac Cardiovasc Surg       Date:  2013-07       Impact factor: 5.209

Review 10.  Positron emission tomography in lung cancer.

Authors:  Hiroaki Nomori; Yasuomi Ohba; Kentaro Yoshimoto; Hidekatsu Shibata; Kenji Shiraishi; Takeshi Mori
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.